Novo Nordisk's Trial Disappointment Intensifies GLP-1 Pricing and Competition Scrutiny

What happened

Novo Nordisk's stock declined 20% after disappointing CagriSema trial results versus Eli Lilly's tirzepatide, underscoring heightened competitive pressures in the GLP-1 market. A Seeking Alpha article advocates buying the dip, citing a P/E of 10.42 and a dividend yield near 4.9%, along with strategic pivots like a digital partnership with Hims. However, DeepValue's analysis reveals deeper challenges: U.S. net prices after rebates declined in 2025, Wegovy and Ozempic lost prescription leadership positions, and illicit compounding persists despite shortage resolution. The investment thesis centers on oral Wegovy expanding the treated patient pool to offset price compression, with a near-term catalyst from $4.2 billion in 340B revenue recognition in 1Q26. Market sentiment has shifted from scarcity-driven growth to a defend-and-reprice narrative, making execution on volume growth critical for re-rating amid ongoing pricing headwinds.

Implication

The CagriSema trial failure exacerbates risks to Novo's market share against Lilly's tirzepatide, potentially accelerating prescription losses in a duopoly market. Attractive valuation metrics like low P/E ratios mask underlying earnings fragility from U.S. rebate pressures and pricing concessions detailed in SEC filings. Oral Wegovy's success hinges on driving net obesity prescription growth beyond injectable cannibalization, with early data needed to confirm PCP adoption and channel partnerships. Investors should watch for the $4.2 billion 340B revenue boost in 1Q26 and subsequent prescription trends to gauge if volume can outpace price compression. Failure to show sustained volume re-acceleration or further pricing erosion could lock in the bear case, capping upside despite seemingly cheap multiples.

Thesis delta

The CagriSema trial setback does not fundamentally alter the core thesis but reinforces the competitive and pricing risks already highlighted in the DeepValue report. It increases the urgency for oral Wegovy to demonstrate volume growth, as the market's focus on defend-and-reprice dynamics intensifies, keeping the investment case contingent on execution against these headwinds over the next 6-12 months.